Warsaw-based Zimmer Biomet Holdings Inc. (NYSE: ZBH) has received U.S. Food and Drug Administration clearance for a device used in shoulder reconstruction surgery. The medical device manufacturer says it has also completed the first surgical case using the Comprehensive Augmented Baseplate.
Zimmer Biomet says the baseplate earned its FDA clearance in January. It is part of the company’s Comprehensive Reverse Shoulder System and the company says it provides an alternative to bone grafting for patients with glenoid defects undergoing shoulder reconstruction.
The surgical case was performed at the Mayo Clinic in Minnesota by orthopedic surgeon John Sperling. Zimmer Biomet says the baseplate allows the clinic to leverage its own methodology to optimize shoulder arthroplasty components developed by Sperling.
The device is the latest by Zimmer Biomet to receive FDA clearance. The company announced in January its Sidus Stem-Free Shoulder system also received the clearance.